For example the following inhibitors are under investigation for mutant ABL1, FLT3 or KIT-associated subtypes (clinicaltrials.gov): sorafenib (e.g. AML: NCT00217646, NCT00373373), sunitinib (e.g. AML: NCT00783653), dasatinib (e.g. CBF-AML: NCT00850382; SM: NCT00979160; Ph + ALL: NCT00103701, NCT00940524), imatinib (e.g. AML: NCT00707408, NCT00744081; activated RTKs/various tumors: NCT00171912), lestaurtinib (e.g. AML: NCT00030186, NCT00079482), tandutinib (e.g. AML: NCT00064584, NCT00274248), masitinib (e.g. SM: NCT00814073) and nilotinib (e.g. AML: NCT01222143; SM/HES: NCT00109707). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.